Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnoCan PharmaFRA:IP40 +0.27%56 EV-to-EBITDA is -12.23 as of Jul. 25, 2026. GuruFocus rates FRA:IP40 with a GF Score™ of 56/100 and a GF Value™ of €8.87 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,642 Consumer Packaged Goods companies, InnoCan Pharma ranks worse than 60901.28% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, InnoCan Pharma's enterprise value is €5.33 Mil.
InnoCan Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.44 Mil. Therefore, InnoCan Pharma's EV-to-EBITDA for today is -12.23.
The historical rank and industry rank for InnoCan Pharma's EV-to-EBITDA or its related term are showing as below:
FRA:IP40'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -86.71 Med: -10.78 Max: 611.15
Current: -10.34
During the past 8 years, the highest EV-to-EBITDA of InnoCan Pharma was 611.15. The lowest was -86.71. And the median was -10.78.
FRA:IP40's EV-to-EBITDA is ranked worse than 100% of 1642
companies
in the Consumer Packaged Goods industry
Industry Median: 8.97
vs FRA:IP40: -10.34
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
InnoCan Pharma's PE Ratio (TTM) for today is calculated as:
InnoCan Pharma's share price for today is €1.89.
InnoCan Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.333.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for InnoCan Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, InnoCan Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma EV-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's EV-to-EBITDA falls into.
InnoCan Pharma's current Enterprise Value is €5.33 Mil.
InnoCan Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCan Pharma (FRA:IP40) has a EV-to-EBITDA of -12.23 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on InnoCan Pharma. According to the industry distribution chart, InnoCan Pharma ranks #999999 out of 1642 companies in the Consumer Packaged Goods industry.
Is InnoCan Pharma's EV-to-EBITDA too high?
InnoCan Pharma's current EV-to-EBITDA is -12.23. Based on the distribution chart, InnoCan Pharma ranks #999999 out of 1642 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, InnoCan Pharma has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's EV-to-EBITDA compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #999999 out of 1642 companies for EV-to-EBITDA. This places InnoCan Pharma in the lower half of its industry. The industry median EV-to-EBITDA is 8.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Consumer Packaged Goods company?
The median EV-to-EBITDA among Consumer Packaged Goods companies is 8.97, based on 1,642 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on InnoCan Pharma. For the Consumer Packaged Goods industry, the median EV-to-EBITDA is 8.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current EV-to-EBITDA is -12.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (FRA:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €8.87, compared to a current price of €1.89 — trading 78.7% below its estimated fair value. The current EV-to-EBITDA is -12.23. InnoCan Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For InnoCan Pharma (FRA:IP40), the current EV-to-EBITDA is -12.23 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (FRA:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.89 is trading 78.7% below its estimated GF Value™ of €8.87.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for FRA:IP40:
EV-to-EBITDA: -12.23
GF Value™: €8.87 vs. price of €1.89 (78.7% below fair value)
No single metric tells the full story. See the FRA:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
56GF Score
Get the complete analysis for FRA:IP40
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IP40 has been successfully added to your 
